# US 2019/0307867 A1 · Anti-abeta therapeutic vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0307867 A1
- Document ID: US20190307867A1
- Status: Published application
- Kind: A1
- Application number: 16/379,322
- Filed: 2019-04-09
- Published: 2019-10-10
- Earliest claimed: 2018-04-10
- Assignees: AC Immune SA
- Applicants: AC Immune SA
- Inventors: Emma Fiorini; Marija Vukicevic Verhille; Maria Pihlgren Bosch
- Web page: https://patentgrep.com/patent/US20190307867A1

## CPC

- A61K 39/0007: {Nervous system antigens; Prions}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 39/0003: {Invertebrate antigens}
- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 39/05: {Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella}, Corynebacterium; Propionibacterium {(Mycobacterium A61K39/04)}
- A61K 39/08: Clostridium, e.g. Clostridium tetani
- A61K 39/245: Herpetoviridae, e.g. herpes simplex virus
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 14/005: from viruses
- C07K 14/43504: {from invertebrates}
- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- C12N 9/1077: {Pentosyltransferases (2.4.2)}
- C12N 9/52: derived from bacteria {or Archaea}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/575: {humoral response}
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- A61K 2039/627: {characterised by the linker}
- A61K 2039/645: {Dendrimers; Multiple antigen peptides}
- A61K 2039/70: {Multivalent vaccine}
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- C12N 2710/16232: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16033: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A liposomal vaccine composition comprises a β-amyloid (Aβ)-derived peptide antigen displayed on the surface of the liposome. The vaccine composition also comprises a peptide comprising a universal T-cell epitope encapsulated within the liposome. The vaccine composition also comprises an adjuvant, which may form part of the liposome and may be displayed at least in part on the surface of the liposome. These vaccine compositions are used for treating, preventing, inducing a protective immune response against or alleviating the symptoms associated with an amyloid-beta associated disease or condition or a condition characterised by, or associated with, loss of cognitive memory capacity in a subject. The vaccine compositions may be provided as a kit. Related methods of producing a liposomal vaccine composition are also provided.

## Claims

### Claim 1

A liposomal vaccine composition comprising:
a. A β-amyloid (Aβ)-derived peptide antigen displayed on the surface of a liposome
b. A peptide comprising a universal T-cell epitope encapsulated within the liposome that stimulates a helper T-cell response that enhances antibody production by B-cells
c. An adjuvant.

### Claim 2 (depends on 1)

The liposomal vaccine composition of claim 1 wherein the peptide comprising a universal T-cell epitope comprises at least 30% hydrophobic amino acids.

### Claim 3 (depends on 1)

The liposomal vaccine composition of claim 1 wherein the liposomal vaccine composition comprises at least two different universal T-cell epitopes encapsulated within the liposome.

### Claim 4 (depends on 3)

The liposomal vaccine composition of claim 3 wherein each universal T-cell epitope is no more than 30 amino acids in length, no more than 20 amino acids in length, or no more than 10-20 amino acids in length.

### Claim 5 (depends on 1)

The liposomal vaccine composition of claim 1 wherein the liposomal vaccine composition comprises two, three or four different universal T-cell epitopes encapsulated within the liposome.

### Claim 6 (depends on 1)

The liposomal vaccine composition of claim 1 wherein the peptide comprising a universal T-cell epitope comprises at least two different universal T-cell epitopes.

### Claim 7 (depends on 1)

The liposomal vaccine composition of claim 1 wherein the peptide comprising a universal T-cell epitope comprises two, three or four universal T-cell epitopes.

### Claim 8 (depends on 7)

The liposomal vaccine composition of claim 7 wherein at least two of the two, three or four universal T-cell epitopes are joined by a linker.

### Claim 9 (depends on 8)

The liposomal vaccine composition of claim 8 wherein the linker comprises at least two amino acids, optionally wherein the linker comprises, consists essentially of or consists of the amino acids VVR or PMGAP.

### Claim 10 (depends on 1)

The liposomal vaccine composition of claim 1 wherein the universal T-cell epitopes are selected from:
a. A combination of a diphtheria toxin and tetanus toxin universal T-cell epitope
b. A combination of an Epstein Barr Virus and tetanus toxin universal T-cell epitope
c. A combination of an Epstein Barr Virus, tetanus toxin and keyhole limpet hemocyanin universal T-cell epitope; or
d. A combination of an influenza hemagglutinin, diphtheria toxin, tetanus toxin and Epstein Barr Virus universal T-cell epitope.

### Claim 11 (depends on 1)

The liposomal vaccine composition of claim 1 wherein the peptide comprising a universal T-cell epitope comprises, consists essentially of or consists of an amino acid sequence selected from SEQ ID NO: 1 (SAT42), SEQ ID NO: 2 (SAT43), SEQ ID NO: 3 (SAT44), SEQ ID NO: 4 (SAT47).

### Claim 12 (depends on 1)

The liposomal vaccine composition of claim 1 wherein the universal T-cell epitope comprises, consists essentially of or consists of an amino acid sequence selected from SEQ ID NO: 5 (SAT6), SEQ ID NO: 6 (SAT13), SEQ ID NO: 7 (SAT15), SEQ ID NO: 8 (SAT17).

### Claim 13 (depends on 1)

The liposomal vaccine composition of claim 1 wherein the adjuvant forms part of the liposome.

### Claim 14 (depends on 1)

The liposomal vaccine composition of claim 1 wherein the adjuvant comprises monophosphoryl lipid A (MPLA).

### Claim 15 (depends on 1)

The liposomal vaccine composition of claim 1 wherein the peptide comprising a universal T-cell epitope is between 30 and 60 amino acids in length.

### Claim 16 (depends on 6)

The liposomal vaccine composition of claim 6 wherein the peptide comprising a universal T-cell epitope is between 30 and 60 amino acids in length.

### Claim 17 (depends on 1)

A method of treating, preventing, inducing a protective immune response against or alleviating the symptoms associated with an amyloid-beta associated disease or condition in a subject comprising administering the liposomal vaccine composition of claim 1 to the subject.

### Claim 18 (depends on 17)

The method of claim 17 wherein the liposomal vaccine composition comprises at least two different universal T-cell epitopes encapsulated within the liposome.

### Claim 19 (depends on 17)

The method of claim 17 wherein the peptide comprising a universal T-cell epitope comprises, consists essentially of or consists of an amino acid sequence selected from SEQ ID NO: 1 (SAT42), SEQ ID NO: 2 (SAT43), SEQ ID NO: 3 (SAT44), SEQ ID NO: 4 (SAT47).

### Claim 20 (depends on 17)

The method of claim 17 wherein the adjuvant forms part of the liposome.

### Claim 21 (depends on 17)

The method of claim 17 wherein the peptide comprising a universal T-cell epitope is between 30 and 60 amino acids in length.

### Claim 22 (depends on 1)

A kit for treating, preventing, inducing a protective immune response against or alleviating the symptoms associated with an amyloid-beta associated disease or condition in a subject comprising the liposomal vaccine composition of claim 1 together with instructions for administering the vaccine composition.

### Claim 23

A liposomal vaccine composition comprising:
a. A tetrapalmitolyated β-amyloid (Aβ)-derived peptide antigen displayed on the surface of the liposome that comprises, consists essentially of or consists of amino acids 1-15 of Aβ
b. A peptide comprising a universal T-cell epitope encapsulated within the liposome wherein the peptide comprising a universal T-cell epitope comprises, consists essentially of or consists of an amino acid sequence of SEQ ID NO: 3 (SAT44)
c. An adjuvant.

### Claim 24 (depends on 23)

The liposomal vaccine composition of claim 23 wherein the adjuvant forms part of the liposome.

### Claim 25 (depends on 23)

The liposomal vaccine composition of claim 23 wherein the adjuvant comprises monophosphoryl lipid A (MPLA).

### Claim 26 (depends on 23)

A method of treating, preventing, inducing a protective immune response against or alleviating the symptoms associated with an amyloid-beta associated disease or condition in a subject comprising administering the liposomal vaccine composition of claim 23 to the subject.

### Claim 27

A liposomal vaccine composition comprising:
a. A tetrapalmitolyated β-amyloid (Aβ)-derived peptide antigen displayed on the surface of the liposome that comprises, consists essentially of or consists of amino acids 1-15 of Aβ
b. A peptide comprising a universal T-cell epitope encapsulated within the liposome wherein the peptide comprising a universal T-cell epitope comprises, consists essentially of or consists of an amino acid sequence of SEQ ID NO: 4 (SAT47)
c. An adjuvant.

### Claim 28 (depends on 27)

The liposomal vaccine composition of claim 27 wherein the adjuvant forms part of the liposome.

### Claim 29 (depends on 27)

The liposomal vaccine composition of claim 27 wherein the adjuvant comprises monophosphoryl lipid A (MPLA).

### Claim 30 (depends on 27)

A method of treating, preventing, inducing a protective immune response against or alleviating the symptoms associated with an amyloid-beta associated disease or condition in a subject comprising administering the liposomal vaccine composition of claim 27 to the subject.
